Porcilis ColiClos

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Clostridium perfringens tip C / Escherichia coli F4ab / E. coli F4ac / E. coli F5 / E. coli F6 / E. coli LT

Available from:

Intervet International BV

ATC code:

QI09AB08

INN (International Name):

vaccine to provide passive immunity to the progeny against Escherichia coli and Clostridium perfringens in pigs

Therapeutic group:

Prašiči

Therapeutic area:

Imunologija

Therapeutic indications:

Za pasivno imunizacijo za potomstvo z aktivno imunizacijo za svinje in brejih za zmanjšanje umrljivosti in kliničnih znakov, ki v prvih dneh življenja, posledica teh sevov Escherichia coli, ki izražajo adhesins F4ab (K88ab), F4ac (K88ac), F5 (K99) ali F6 (987P) in povzroča Clostridium perfringens tip C.

Product summary:

Revision: 5

Authorization status:

Pooblaščeni

Authorization date:

2012-06-14

Patient Information leaflet

                                16
B. NAVODILO ZA UPORABO
17
NAVODILO ZA UPORABO
PORCILIS COLICLOS SUSPENZIJA ZA INJICIRANJE ZA PRAŠIČE
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
IMETNIKA DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVORNEGA ZA
SPROSTITEV SERIJE V EGP, ČE STA RAZLIČNA
Imetnik dovoljenja za promet z zdravilom:
Intervet International B.V.
Wim de Körverstraat 35
NL-5831 AN Boxmeer
Nizozemska
Proizvajalec, odgovoren za sproščanje serij:
Intervet International B.V.
Wim de Körverstraat 35
NL-5831 AN Boxmeer
Nizozemska
MSD Animal Health UK Ltd
Walton Manor, Walton, Milton Keynes
Buckinghamshire, MK7 7AJ, Združeno kraljestvo
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Porcilis ColiClos suspenzija za injiciranje za prašiče
3.
NAVEDBA ZDRAVILNE(IH) UČINKOVIN(E) IN DRUGE(IH) SESTAVIN
Vsak odmerek po 2 ml vsebuje:
ZDRAVILNE UČINKOVINE:
Kompopnente
_E. coli_
:
- fimbrijski adhezin F4ab
titer protiteles

9,7 log
2
1
- fimbrijski adhezin F4ac
titer protiteles

8,1 log
2
1
- fimbrijski adhezin F5
titer protiteles

8,4 log
2
1
- fimbrijski adhezin F6
titer protiteles

7,8 log
2
1
- toksoid LT
titer protiteles

10,9 log
2
1
Komponenta
_ C. perfringens_
:
- beta toksoid tip C (sev 578)
≥20 IE
2
1
Srednji titer protiteles po cepljenju miši z 1/20 ali 1/40 odmerka za
svinje.
2
Internacionalne enote beta antitoksina po Ph. Eur.
DODATEK
dl-

-tokoferilacetat
150 mg
Vodna, bela do skoraj bela suspenzija za injiciranje za prašiče
4.
INDIKACIJA(E)
18
Pasivna imunizacija pujskov z aktivno imunizacijo svinj in mladic. S
tem se zmanjša smrtnost in
klinični znaki v prvih dnevih po rojstvu, ki jo povzročajo sevi
_E.coli_
, ki izločajo fimbrijske adhezine
F4ab (K88ab), F4ac (K88ac), F5 (K99) ali F6 (987P) in ki jih povzroča
tip C
_C. perfringens._
5.
KONTRAINDIKACIJE
Jih ni.
6.
NEŽELENI UČINKI
_V laboratorijskih študijah in terenskih preskušanjih: _
Prehodno povišanje telesne temperature za približno 2 ºC je b ilo
zelo pogosto opaženo na dan
cepljenja. Zmanjšana aktivnost in pomanjkanje apeti
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATEK I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 26-06-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 26-06-2020
Public Assessment Report Public Assessment Report Bulgarian 13-06-2013
Patient Information leaflet Patient Information leaflet Spanish 26-06-2020
Public Assessment Report Public Assessment Report Spanish 13-06-2013
Patient Information leaflet Patient Information leaflet Czech 26-06-2020
Public Assessment Report Public Assessment Report Czech 13-06-2013
Patient Information leaflet Patient Information leaflet Danish 26-06-2020
Public Assessment Report Public Assessment Report Danish 13-06-2013
Patient Information leaflet Patient Information leaflet German 26-06-2020
Public Assessment Report Public Assessment Report German 13-06-2013
Patient Information leaflet Patient Information leaflet Estonian 26-06-2020
Public Assessment Report Public Assessment Report Estonian 13-06-2013
Patient Information leaflet Patient Information leaflet Greek 26-06-2020
Public Assessment Report Public Assessment Report Greek 13-06-2013
Patient Information leaflet Patient Information leaflet English 26-06-2020
Public Assessment Report Public Assessment Report English 13-06-2013
Patient Information leaflet Patient Information leaflet French 26-06-2020
Public Assessment Report Public Assessment Report French 13-06-2013
Patient Information leaflet Patient Information leaflet Italian 26-06-2020
Public Assessment Report Public Assessment Report Italian 13-06-2013
Patient Information leaflet Patient Information leaflet Latvian 26-06-2020
Public Assessment Report Public Assessment Report Latvian 13-06-2013
Patient Information leaflet Patient Information leaflet Lithuanian 26-06-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 26-06-2020
Public Assessment Report Public Assessment Report Lithuanian 13-06-2013
Patient Information leaflet Patient Information leaflet Hungarian 26-06-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 26-06-2020
Public Assessment Report Public Assessment Report Hungarian 13-06-2013
Patient Information leaflet Patient Information leaflet Maltese 26-06-2020
Public Assessment Report Public Assessment Report Maltese 13-06-2013
Patient Information leaflet Patient Information leaflet Dutch 26-06-2020
Public Assessment Report Public Assessment Report Dutch 13-06-2013
Patient Information leaflet Patient Information leaflet Polish 26-06-2020
Public Assessment Report Public Assessment Report Polish 13-06-2013
Patient Information leaflet Patient Information leaflet Portuguese 26-06-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 26-06-2020
Public Assessment Report Public Assessment Report Portuguese 13-06-2013
Patient Information leaflet Patient Information leaflet Romanian 26-06-2020
Public Assessment Report Public Assessment Report Romanian 13-06-2013
Patient Information leaflet Patient Information leaflet Slovak 26-06-2020
Public Assessment Report Public Assessment Report Slovak 13-06-2013
Patient Information leaflet Patient Information leaflet Finnish 26-06-2020
Public Assessment Report Public Assessment Report Finnish 13-06-2013
Patient Information leaflet Patient Information leaflet Swedish 26-06-2020
Public Assessment Report Public Assessment Report Swedish 13-06-2013
Patient Information leaflet Patient Information leaflet Norwegian 26-06-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 26-06-2020
Patient Information leaflet Patient Information leaflet Icelandic 26-06-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 26-06-2020
Patient Information leaflet Patient Information leaflet Croatian 26-06-2020